M&A Deal Summary |
|
|---|---|
| Date | 2024-11-06 |
| Target | Avid Bioservices |
| Sector | Life Science |
| Buyer(s) |
Ampersand Capital Partners
GHO Capital Partners |
| Deal Type | Going Private |
| Deal Value | 1.1B USD |
| Advisor(s) | Moelis & Co. (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 83 of 84 |
| Sector (Life Science) | 42 of 43 |
| Type (Going Private) | 2 of 2 |
| State (California) | 12 of 12 |
| Country (United States) | 68 of 69 |
| Year (2024) | 4 of 5 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-11-04 |
Nektar - Commercial PEGylation Reagent Manufacturing Business
Huntsville, Alabama, United States Nektar's Commercial PEGylation Reagent Manufacturing Business site is a 124,000-square-foot, commercial-scale specialized manufacturing facility. Nektar's Commercial PEGylation Reagent Manufacturing Business is based in Huntsville, Alabama. |
Buy | $90M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-02 |
Gannet BioChem
Huntsville, Alabama, United States Gannet BioChem is a specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents essential components in advanced biopharmaceutical and therapeutic products. Gannet BioChem is based in Huntsville, Alabama. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2014 |
| PE ASSETS | 6.0B EUR |
| Size | Mega |
| Type | Sector Focused |
GHO Capital Partners is a private investment firm focused on the healthcare sector. The Firm will consider opportunities throughout Europe and seeks well-established, profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. GHO Capital Partners was established in 2014 and is based in London, England.
| DEAL STATS | # |
|---|---|
| Overall | 20 of 20 |
| Sector (Life Science) | 14 of 14 |
| Type (Going Private) | 1 of 1 |
| State (California) | 3 of 3 |
| Country (United States) | 9 of 9 |
| Year (2024) | 2 of 2 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-01 |
FairJourney Biologics
Porto, Portugal FairJourney Biologics is a biologics CRO, providing integrated services across antibody discovery, engineering, and production to global biopharma. The company operates a flexible, customer-oriented ‘one-stop-shop’ approach to biologics development focused on quality, reliability, and partnership. FairJourney Biologics was founded in 2012 and is based in Porto, Portugal. |
Sell | - |
